Medtronic has launched its mySentry remote glucose monitor in the US following approval from the Food and Drug Administration (FDA).
The mySentry remote glucose monitor is used along with the MiniMed Paradigm REAL-Time Revel system, an insulin pump with built-in continuous glucose monitoring. MySentry facilitates healthcare providers to see real-time insulin pump status and glucose trends, as well as hear alerts and alarms, at their bedside while an adult or child with diabetes sleeps in his or her own room.
The continuous monitoring will allow parents or caregivers to monitor their child’s glucose levels at their bedside, enabling them to take action to prevent an episode of low blood sugar (hypoglycemia). MySentry can be placed in the bedroom or in any room throughout the house, providing flexibility and a variety of advantages such as displaying all the alerts and alarms available on the Paradigm Revel insulin pump.
Yale Center Clinical Investigation deputy director William Tamborlane said improvements in continuous glucose monitoring, including remote monitoring like mySentry, have given parents an added level of protection from dangerous nighttime hypoglycemia occurring in their sleeping child, as well as a means to enhance their quality of life. "Many of the parents of our patients wake up a couple of times every night to check their child’s blood sugar level and even that may not be enough to prevent episodes of severe hypoglycemia," he added.
Medtronic Continuous Glucose Monitoring business vice-president and general manager Greg Meehan said that the mySentry remote glucose monitor will help people to manage their diabetes by accessing the wealth of information captured by the company’s integrated insulin pump and continuous glucose monitoring (CGM) system.
The remote glucose monitor also underlines the launch of a new category of connected care solutions that will enable people with diabetes and their caregiver’s convenient options to access their diabetes management information.